Radiofrequency Ablation After Total Knee Arthroplasty

Chronic Knee Pain Clinical Trial

— RACKTKA  

Official title:

A 6-month, Double-blinded, Sham-controlled Clinical Trial Assessing the Clinical Usefulness of Radiofrequency Ablation for Chronic Knee Pain After Total Knee Arthroplasty

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05473663
• Other study ID #: RACK TKA
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2022
• Est. completion date: August 2024

Study information

• Verified date: December 2023
• Source: Tufts Medical Center
• Contact: Timothy E McAlindon, MD, MPH
• Phone: 617-636-5645
• Email: tmcalindon[@]tuftsmedicalcenter.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess how clinically useful and safe genicular nerve radiofrequency ablation is in people with chronic pain after total knee arthroplasty performed for osteoarthritis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Eligible individuals over 18 years of age in general good health apart from their chronic knee pain

2. At least one year post-TKA

3. Report of chronic knee pain classified using a standard question about the presence of "pain, aching, or stiffness in the knee on most days for at least one month during the prior 6 months"

4. In an unacceptable symptom state classified using a validated question: "Think about all consequences of your arthroplasty in the last week. If you were to remain for the rest of your life as you were during the last week, would the current state be acceptable or unacceptable for you?"

5. Willingness to complete all the study procedures, including a daily pain NRS, AE, and medication usage questions via daily notification

6. Subjects must have read and understood the informed consent form (ICF), and must have signed and dated it prior to any study-related procedure being performed

Exclusion Criteria:

1. Pregnant women, breastfeeding women, and women who are not post-menopausal (defined at 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy)

2. Women who are not post-menopausal or permanently surgically sterile who are sexually active, and who are not willing to use birth control as outlined in Section 5.3.1 during the study period

3. Significant evidence of infection within the knee or radiographic evidence of prosthesis loosening as defined by the orthopedic surgeon

4. Individuals with pain exclusively located in the posterior knee, evaluated systematically using a validated Knee Pain Map

5. Individuals who do not achieve a 70% pain reduction following the initial prognostic block, consistent with clinical practice

6. Participation in a clinical research trial that included the receipt of an investigational product (IP) or any experimental therapeutic procedure within 30 days prior to the Screening Visit, or planned participation in any such trial

7. Use of anticoagulants and inability to withhold for three days prior to the study RFA procedure with clearance by the prescribing physician

8. Other conditions that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation

Related Conditions & MeSH terms

• Chronic Knee Pain

Intervention

Device:
• Radiofrequency Ablation
Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.
• Sham
Is performed identically to the active treatment but without the application of the RFA current

Locations

Country	Name	City	State
United States	Tufts Medical Center	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Tufts Medical Center	Boston University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acceptability by actively treated participants Outcome	Our a priori decision rule for acceptability of RFA will be that 50% of the actively treated participants respond affirmatively at the 3-month visit: "Would you recommend the treatment used in this study to someone in a similar situation with knee pain after a knee replacement?"	3 months
Primary	Safety Outcome	<2 serious adverse events among 20 actively treated participants. After enrollment, participants will complete training regarding the daily notification for daily adverse event monitoring. During the study, participants will be automatically prompted daily to report adverse events on their mobile device or home computer. If a participant does not complete adverse event monitoring daily, a member of the study team will contact them to troubleshoot.; Additionally, a more thorough examination of patient safety will be conducted during the clinical exam in the 1-, 3-, and 6-month follow-up visits. Prosthesis safety will be assessed with skyline, lateral, and anteroposterior radiographs (e.g. aseptic loosening, osteolysis) at baseline and 6 months69. Serious adverse events will be consistent with our institution's IRB definitions and with a definition of serious adverse drug experience in FDA 21 CFR 312.32(a).	6 months
Primary	Efficacy Outcome	<5 number needed to treat to achieve a patient-acceptable symptom state. Patient acceptable symptom state will be defined with the following question: "Think about all consequences of your arthroplasty in the last week. If you were to remain for the rest of your life as you were last week, would the current state be acceptable or unacceptable for you?"61 Primary efficacy measure will be whether a participant considers themselves in an acceptable symptom state at the 3-month visit after the intervention. A <5 number is needed to treat to achieve a patient-acceptable symptom state.	3 months
Secondary	Pain Number Rating Score (NRS)	Change from baseline in daily pain number rating scale (NRS) scores via text or online platform until study completion. Min= 0, Max=10. Larger change in scores mean a better outcome.	6 months
Secondary	Knee Injury and Osteoarthritis Outcome Score (KOOS)	Change from baseline in the Knee Injury and Osteoarthritis Outcome Score (KOOS) Activities of Daily Living subscales at 1-, 3-, and 6-month visits. Questions measured from 0-4. Min = 0 (none), Max= 4 (extreme). Larger change in scores mean a better outcome.	1-, 3-, and 6-month visits
Secondary	Physical Activity Scale for the Elderly (PASE)	Change from baseline in the Physical Activity Scale for the Elderly (PASE) at 1-, 3-, and 6-month visits. Measured based on frequency 0 (never)- 3 (often). Larger change in score means better outcome.	1-, 3-, and 6-month visits
Secondary	Quality of Life Measured using Knee Injury and Osteoarthritis Outcome Score Quality of Life (KOOS QOL)	Change from baseline in the KOOS Quality of Life subscale at 1-, 3-, and 6-month visits. not at all- extreme. Larger change in score means better outcome.	1-, 3-, and 6-month visits
Secondary	Quality of Life Measured using Patient Reported Outcome Measurement Information System (PROMIS) Global 10	Change from baseline in the PROMIS Global 10 at 1-, 3-, and 6-month visits.	1-, 3-, and 6-month visits
Secondary	Walk Test	Change from baseline in 20-meter walk test time at 1-, 3-, and 6 month visits	1-, 3-, and 6-month visits
Secondary	Chair Stand Test	Change from baseline in chair stand speed at 1-, 3-, and 6- month visits	1-, 3-, and 6-month visits
Secondary	Daily Step Count	Change from baseline in daily step count via Wearable Activity Monitor (i.e. Fitbit) averaged over the one week following 1-, 3-, and 6- month visits	1-, 3-, and 6-month visits
Secondary	Incidence of Pain Medication use	Change from baseline in usage of pain medication for target knee pain at 1-, 3-, and 6- month visits. Measured using questionnaire.	1-, 3-, and 6-month visits
Secondary	Gait Analysis	An optional sub-study will assess change from baseline in spatiotemporal metrics of gait at the 3 month visit. . Data collected will include knee kinematics and kinetics using optical motion capture and spatiotemporal gait parameters using wearable inertial sensors. Larger change from baseline means better outcome.	3 months